ArticleBreast cancer : basic and clinical research2018

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.

Hiroyasu Yamashiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.